| ||||||||||||||||||||||||||||||||||||
|
:: November 2009 Welcome to our Monthly Online Newsletter!View all Treatment articles in our Treatment Report . The most recent articles are listed on top (not in alphabetical order). Click on the Topic on our home page and then the subtopic - Treatment Report. Stay updated on drugs and their side effects, and various other treatments, including exercise, nutrition, and supplements. Highlighted ArticleReport: Prostate cancer screening has yet to prove its worth “The recent release of two large randomized trials suggests that if there is a benefit of screening, it is, at best, small, says a new report in CA: A Cancer Journal for Clinicians. Authored by Otis W. Brawley, M.D. of the American Cancer Society and Donna Ankerst, Ph.D. and Ian M. Thompson, M.D. of the University of Texas Health Science Center at San Antonio, the review says because prostate cancer is virtually ubiquitous in men as they age, it is clear that a goal of "finding more cancers" is not acceptable. Instead, public health principles demand that screening must reduce the risk of death from prostate cancer, reduce the suffering from prostate cancer, or reduce health care costs when compared with a non-screening scenario. The authors suggest prostate cancer screening has yet to reach one of these standards to date. No major medical group, including the American Cancer Society, currently recommends routine prostate cancer screening for men at average risk. In the United States, prostate cancer will affect one man in six men during his lifetime. Since the mid-1980s, screening with the prostate–specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. The review says a decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved treatment, has been uncertain.” Clinical GuidelinesESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer (2005) NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection (2007) NCCN - Prostate Cancer Treatment Guidelines for Patients ø Version V, September 2005 New Guidelines Recommend 5-Alpha Reductase Inhibitors for Preventing Prostate Cancer NGC - ACR Appropriateness Criteria for pretreatment staging of clinically localized prostate cancer. NGC - GUIDELINE SYNTHESIS SCREENING FOR PROSTATE CANCER NGC - Locally advanced (high-risk) prostate cancer. (2006) NGC - Maximal androgen blockade for the treatment of metastatic prostate (2003) NGC - NATIONAL GUIDELINE CLEARINGHOUSE™ (NGC) GUIDELINE SYNTHESIS: SCREENING FOR PROSTATE CANCER (2007 ) NGC - Node-positive prostate cancer. (2006) NGC - Obstructive voiding symptoms secondary to prostate disease. (2005) NGC - Post-treatment follow-up of prostate cancer. (2005) NGC - Pretreatment staging prostate cancer. (2005) NGC - Prostate cancer. (2005) NGC - Screening for prostate cancer in U.S. men: ACPM position statement on preventive practice. (2008) NGC - Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. (2008) NGC - The use of bisphosphonates in men with hormone-refractory prostate cancer. (2005) Internet SitesFeatured siteNCI - Background on Prostate Cancer NCI - Early Prostate Cancer: Questions and Answers NCI - General Information About Prostate Cancer NCI - Genetics of Prostate Cancer NCI - Know Your Options: Understanding Treatment Choices for Prostate Cancer NCI - Prostate Cancer (PDQ¬): Prevention NCI - Prostate Cancer (PDQ®): Screening (professional version) NCI - Prostate Cancer (PDQ®): Screening (patient version) NCI - Prostate Cancer (PDQ¬): Treatment NCI - Understanding Prostate Changes: A Health Guide for Men Related InfoMedSearch TopicsRelated Topics - Highlighted Articles
ProstatitisSexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case-control study in Wayne County, Michigan. (Cancer Causes Control. 2005) "Conclusions: Among all subjects, prostate cancer was associated with prostatitis and BPH history, but not with STD or vasectomy history."
Benign Prostatic HyperplasiaFamily history of cancer and the risk of prostate cancer and benign prostatic hyperplasia. (Int J Cancer. 2005) "Our study adds further information on the association of family history of cancer and risk of PC and is, to our knowledge, the first comprehensive epidemiologic information on family history of cancer and risk of BPH."
|
|
|||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||